Weight Loss & Metabolic / side effects and safety / Last reviewed 2026-04-04

Dulaglutide Side Effects: Safety Signals and Warnings

Dulaglutide safety concerns are compound-specific. The main listed side effects are Nausea, Diarrhea, and Vomiting. The main warning signals are Boxed warning: Thyroid C-cell tumor risk in rodents, Contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2, and Risk of pancreatitis - discontinue if suspected.

Read the full Dulaglutide guide Browse answer pages

Direct Answer

Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, with the REWIND trial demonstrating significant CV event reduction in a broad diabetic population. As a once-weekly GLP-1 agonist, it offers meaningful convenience. Its weight-loss efficacy is modest compared to semaglutide, but its CV outcome data is robust. A well-validated option for GLP-1 pathway research with strong regulatory backing.

Evidence grade
Level A
Research status
FDA Approved
Category
Weight Loss & Metabolic
Best for
Type 2 diabetes management, cardiovascular risk reduction, once-weekly GLP-1 agonism

Reported Side Effects

Warnings

Known or Plausible Interactions

Regulatory Context

FDA approved (2014). Prescription required. Not a controlled substance.

Evidence Snapshot

Evidence gradeLevel A
Research statusFDA Approved
Best supported outcomesGlycemic Control (Level A), Cardiovascular Risk Reduction (Level A), and Body Weight Reduction (Level A)
Primary citation count3
Last reviewed2026-04-04

Related Guides

How to Cite This Page

ExaminePeptides. "Dulaglutide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/dulaglutide-side-effects-safety/

This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.